Expression of the 5-HT1A serotonin receptor in the hippocampus is required for social stress resilience and the antidepressant-like effects induced by the nicotinic partial agonist cytisine

Neuropsychopharmacology

Volumn 40, Issue 4, 2015, Pages 938-946

  Mineur, Yann S ^a   Einstein, Emily B ^a   Bentham, Matthew P ^a   Wigestrand, Mattis B ^a   Blakeman, Sam ^a   Newbold, Sylvia A ^a   Picciotto, Marina R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CYTISINE; FLUOXETINE; SEROTONIN 1A RECEPTOR; ALKALOID; ANTIDEPRESSANT AGENT; AZOCINE DERIVATIVE; QUINOLIZINE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTONIN RELEASE; SOCIAL STRESS; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG THERAPY; ETIOLOGY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HUMAN; HUMAN RELATION; IMMOBILIZATION; MENTAL STRESS; METABOLISM; MOTOR ACTIVITY; PATHOLOGY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ALKALOIDS; ANIMALS; ANTIDEPRESSIVE AGENTS; AZOCINES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FLUOXETINE; GENE EXPRESSION REGULATION; HEK293 CELLS; HINDLIMB SUSPENSION; HIPPOCAMPUS; HUMANS; INTERPERSONAL RELATIONS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; QUINOLIZINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN RECEPTOR AGONISTS; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL;

EID: 84925539443     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.269     Document Type: Article

References (57)

1. Abdel-Fattah AF, Matsumoto K, Murakami Y, Adel-Khalek Gammaz H, Mohamed MF, Watanabe H (1997). Central serotonin level-dependent changes in body temperature following administration of tryptophan to pargyline-and harmalinepretreated rats. Gen Pharmacol 28: 405-409.
2. Andreasen JT, Redrobe JP, Nielsen EO (2012). Combined alpha7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacol Biochem Behav 100: 624-629.
3. Araragi N, Lesch KP (2013). Serotonin (5-HT) in the regulation of depression-related emotionality: insight from 5-HT transporter and tryptophan hydroxylase-2 knockout mouse models. Curr Drug Targets 14: 549-570.
4. Bacher I, Wu B, Shytle DR, George TP (2009). Mecamylamine-a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. Expert Opin Pharmacother 10: 2709-2721.
5. Banasr M, Hery M, Printemps R, Daszuta A (2004). Serotonininduced increases in adult cell proliferation and neurogenesis are mediated through different and common 5-HT receptor subtypes in the dentate gyrus and the subventricular zone. Neuropsychopharmacology 29: 450-460.
6. Benavides DR, Quinn JJ, Zhong P, Hawasli AH, DiLeone RJ, Kansy JW et al (2007). Cdk5 modulates cocaine reward, motivation, and striatal neuron excitability. J Neurosci 27: 12967-12976.
7. Brezun JM, Daszuta A (2000). Serotonin may stimulate granule cell proliferation in the adult hippocampus, as observed in rats grafted with foetal raphe neurons. Eur J Neurosci 12: 391-396.
8. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science (New York, NY) 301: 386-389.
9. Colino A, Halliwell JV (1987). Differential modulation of three separate K-conductances in hippocampal CA1 neurons by serotonin. Nature 328: 73-77.
10. Cryan JF, Mombereau C, Vassout A (2005). The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29: 571-625.
11. De Vivo M, Maayani S (1986). Characterization of the 5-hydroxytryptamine1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther 238: 248-253.
12. Drevets WC Jr., Zarate CA, Furey ML (2012). Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry 73: 1156-1163.
13. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G (2012). Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62: 35-41.
14. Duric V, Duman RS (2013). Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell Mol Life Sci 70: 39-53.
15. Fenster CP, Rains MF, Noerager B, Quick MW, Lester RA (1997). Influence of subunit composition on desensitization of neuronal acetylcholine receptors at low concentrations of nicotine. J Neurosci 17: 5747-5759.
16. File SE, Kenny PJ, Cheeta S (2000). The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem Behav 66: 65-72.
17. Furey ML, Drevets WC (2006). Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebocontrolled clinical trial. Arch Gen Psychiatry 63: 1121-1129.
18. Gartside SE, Hajos-Korcsok E, Bagdy E, Harsing LG Jr., Sharp T, Hajos M (2000). Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience 98: 295-300.
19. George TP, Sacco KA, Vessicchio JC, Weinberger AH, Shytle RD (2008). Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol 28: 340-344.
20. Ginefri-Gayet M, Gayet J (1993). Hypothermia induced by infusion of methionine sulfoximine into the dorsal raphe nucleus of the rat: involvement of 5-HT1A and GABAB receptors. Eur J Pharmacol 235: 189-196.
21. Ginsberg LD (2009). Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. CNS Spectr 14: 8-14.
22. Grady SR, Marks MJ, Collins AC (1994). Desensitization of nicotine-stimulated [3H]dopamine release from mouse striatal synaptosomes. J Neurochem 62: 1390-1398.
23. Grahn RE, Will MJ, Hammack SE, Maswood S, McQueen MB, Watkins LR et al (1999). Activation of serotonin-immunoreactive cells in the dorsal raphe nucleus in rats exposed to an uncontrollable stressor. Brain Res 826: 35-43.
24. Han C, Yeh TL, Kato M, Sato S, Chang CM, Pae CU (2013). Management of chronic depressive patients with residual symptoms. CNS Drugs 27: S53-S57.
25. Hannestad JO, Cosgrove KP, DellaGioia NF, Perkins E, Bois F, Bhagwagar Z et al (2013). Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. Biol Psychiatry 74: 768-776.
26. Heim C, Owens MJ, Plotsky PM, Nemeroff CB (1997). Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. Psychopharmacol Bull 33: 185-192.
27. Hensler JG, Advani T, Monteggia LM (2007). Regulation of serotonin-1A receptor function in inducible brain-derived neurotrophic factor knockout mice after administration of corticosterone. Biol Psychiatry 62: 521-529.
28. Hommel JD, Sears RM, Georgescu D, Simmons DL, DiLeone RJ (2003). Local gene knockdown in the brain using viral-mediated RNA interference. Nat Med 9: 1539-1544.
29. Kang M, Pyun KH, Jang CG, Kim H, Bae H, Shim I (2005). Nelumbinis Semen reverses a decrease in hippocampal 5-HT release induced by chronic mild stress in rats. J Pharm Pharmacol 57: 651-656.
30. Kenny PJ, File SE, Neal MJ (2000). Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem 75: 2409-2414.
31. Khadrawy YA, El-Shamy KA, Mohamed SI (2011). Nicotine restores monoamine neurotransmitter changes in the cortex and hippocampus of reserpinized rats as a model of depression. Eur Rev Med Pharmacol Sci 15: 863-870.
32. Lucki I, O'Leary OF (2004). Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 65: 11-24.
33. Lucki I, Wieland S (1990). 5-Hydroxytryptamine1A receptors and behavioral responses. Neuropsychopharmacology 3: 481-493.
34. Luo DD, An SC, Zhang X (2008). Involvement of hippocampal serotonin and neuropeptide Y in depression induced by chronic unpredicted mild stress. Brain Res Bull 77: 8-12.
35. Luscher C, Jan LY, Stoffel M, Malenka RC, Nicoll RA (1997). G protein-coupled inwardly rectifying K channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron 19: 687-695.
36. Mahar I, Bambico FR, Mechawar N, Nobrega JN (2014). Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci Biobehav Rev 38: 173-192.
37. Mineur YS, Abizaid A, Rao Y, Salas R, DiLeone RJ, Gundisch D et al (2011). Nicotine decreases food intake through activation of POMC neurons. Science (New York, NY) 332: 1330-1332.
38. Mineur YS, Eibl C, Young G, Kochevar C, Papke RL, Gundisch D et al (2009). Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J Pharmacol Exp Ther 329: 377-386.
39. Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM et al (2013). Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety-and depression-like behavior. Proc Natl Acad Sci USA 110: 3573-3578.
40. Mineur YS, Picciotto MR, Sanacora G (2007a). Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry 61: 250-252.
41. Mineur YS, Somenzi O, Picciotto MR (2007b). Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology 52: 1256-1262.
42. Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH et al (2006). Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 163: 1630-1633.
43. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH (2009). Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry 70: 1026-1031.
44. Preston TC, Shelton RC (2013). Treatment resistant depression: strategies for primary care. Curr Psychiatry Rep 15: 370.
45. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Sitaram N, Gillin JC et al (1981). Physostigmine induction of depressive symptomatology in normal human subjects. Psychiatry Res 4: 89-94.
46. Rollema H, Guanowsky V, Mineur YS, Shrikhande A, Coe JW, Seymour PA et al (2009). Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol 605: 114-116.
47. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S et al (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (New York, NY) 301: 805-809.
48. Saricicek A, Esterlis I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A et al (2012). Persistent beta2-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry 169: 851-859.
49. Sheard MH, Aghajanian GK (1967). Neural release of brain serotonin and body temperature. Nature 216: 495-496.
50. Shytle RD, Silver AA, Lukas RJ, Newman MB, Sheehan DV, Sanberg PR (2002a). Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 7: 525-535.
51. Shytle RD, Silver AA, Sheehan KH, Sheehan DV, Sanberg PR (2002b). Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety 16: 89-92.
52. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85: 367-370.
53. Vieta E, Thase ME, Naber D, D'Souza B, Rancans E, Lepola U et al (2013). Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant. Eur Neuropsychopharmacol 24: 564-574.
54. Vogel C, Marcotte EM (2012). Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13: 227-232.
55. Wieland S, Lucki I (1990). Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 101: 497-504.
56. Wilkinson MB, Dias C, Magida J, Mazei-Robison M, Lobo M, Kennedy P et al (2011). A novel role of the WNT-dishevelled-GSK3beta signaling cascade in the mouse nucleus accumbens in a social defeat model of depression. J Neurosci 31: 9084-9092.
57. Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K et al (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 6: 973-985.